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Abstract
Objectives To develop a consensus and provide updated rec-
ommendations on liver MR imaging and the clinical use of
liver-specific contrast agents.
Methods The European Society of Gastrointestinal and Ab-
dominal Radiology (ESGAR) formed a multinational Europe-
an panel of experts, selected on the basis of a literature review
and their leadership in the field of liver MR imaging. A mod-
ified Delphi process was adopted to draft a list of statements.
Descriptive and Cronbach’s statistics were used to rate levels
of agreement and internal reliability of the consensus.
Results Three Delphi rounds were conducted and 76 state-
ments composed on MR technique (n=17), clinical application
of liver-specific contrast agents in benign, focal liver lesions
(n=7), malignant liver lesions in non-cirrhotic (n=9) and in
cirrhotic patients (n=18), diffuse and vascular liver diseases
(n=12), and bile ducts (n=13). The overall mean score of
agreement was 4.84 (SD ±0.17). Full consensus was reached
in 22 % of all statements in all working groups, with no full
consensus reached on diffuse and vascular diseases.
Conclusions The consensus provided updated recommenda-
tions on the methodology, and clinical indications, of MRI
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with liver specific contrast agents in the study of liver
diseases.
Key points
• Liver-specific contrast agents are recommended in MRI of
the liver.
• The hepatobiliary phase improves the detection and charac-
terization of hepatocellular lesions.
• Liver-specific contrast agents can improve the detection of
HCC.
Keywords Liver . Biliary tract . Magnetic resonance
imaging . Contrast media . Delphi technique
Introduction
The advantages of MR imaging in the investigation of the
liver are well documented since this examination provides a
comprehensive work-up of focal and diffuse liver diseases.
Recent state-of-the-art techniques including fast scanning ac-
quisitions and new MR imaging contrast agents enable im-
provements in detection and characterization of focal liver
lesions. Therefore, together with appropriate clinical informa-
tion, in most cases, a definitive diagnosis can be adequately
achieved avoiding invasive procedures such as liver biopsy.
This is based on the unique properties of MR imaging
resulting in a high intrinsic soft tissue contrast between normal
liver parenchyma and liver lesions, which can be further en-
hanced with intravenous administration of non-specific
(extracellular) and liver-specific (hepatobiliary) gadolinium-
based contrast agents [1–4].
Multiphasic dynamic gadolinium-enhanced imaging,
which is considered essential in detection and characterization
of liver lesions, is routinely obtained by using non-specific
intravenous contrast agents that distribute in the extracellular
space, both within and outside the vessels, and have imaging
dynamics comparable to the extracellular iodinated contrast
media used in CT [5, 6].
The so-called liver-specific (or hepatobiliary) contrast
agents (gadobenate dimeglumine, Gd-BOPTA, and gadoxetic
acid, Gd-EOB-DTPA), are characterized by a dual behaviour:
by exhibiting elimination through both renal and hepatic ex-
cretion pathways and thereby possessing both early perfusion
information (renal elimination pathway) and, later,
hepatocyte-selective information (hepatic excretion pathway)
mediated through protein transporters, located in the canalic-
ular or sinusoidal pole of the hepatocytes [7–9].
The liver-specific contrast agents are Gd-based compounds
and, therefore, shorten the T1 relaxation time that results in an
increased signal intensity of the healthy liver parenchyma on
T1-weighted images [8, 10].
The clinical use of liver-specific contrast agents allows the
physician to obtain morphologic and vascular-related
information, thanks to the dynamic study, as well as functional
information, thanks to the hepatocyte-selective phase of en-
hancement. However, even if a large number of research and
review articles on the use of liver-specific contrast agents in
different clinical scenarios have already been published,
agreement about their clinical indication is still lacking
[11–16].
To develop a consensus and provide updated recommen-
dations on the bestMRI technique and the clinical use of liver-
specific contrast agents, the European Society of Gastrointes-
tinal and Abdominal Radiology (ESGAR) recruited a working
group of key opinion leaders in the field of liver MR imaging.
Materials and method
Consensus panel
The working group, composed of a multinational European
panel of 18 members and faculty of the ESGAR (composed of
X.X.,1 B.M.A., M.A., B.P., B.G., CA.F., G.F., H.T., L.J.M.,
M.R., MB.L., M.C., M.EM., ODB.B., S.W., S.S., V.V., Z.C.),
used a modified Delphi process to rate the level of agreement
on numerous statements pertaining to the MR imaging tech-
nique and the clinical applications of liver-specific contrast
agents [17]. Two additional panellists, who did not express a
vote, were chosen to play the role of facilitators (C.B. and
E.N.).
Three Delphi rounds were conducted. In the first round, the
panellists had a face-to-face meeting and, on the basis of their
main area of research and expertise, were split into six work-
ing groups (WG) onMR technique (WG 1), benign focal liver
lesions (WG 2), malignant liver lesions in non-cirrhotic pa-
tients (WG 3), focal liver lesions in cirrhotic patients (WG 4),
diffuse and vascular liver diseases (WG 5), and bile duct ap-
plications (WG 6). Each WG independently drafted a cluster
of statements pertaining to their allocated subject. A prelimi-
nary literature review for eachWG to support the composition
of statements was based on the GRADE system [18]. Each
WG then presented the proposed statements to the whole pan-
el for detailed discussion. At this time, the content and word-
ing of statements were modified until a general consensus
emerged.
In the second and third rounds the panellists were sent
electronic copies of the latest statements in order to rate inde-
pendently their level of agreement using a 5-point Likert scale
as follows: 1, strongly disagree with the statement; 2, disagree
somewhat with the statement; 3, undecided; 4, agree some-
what with the statement; 5, strongly agree with the statement.
To reach the maximum consensus, the number and content of
1 X.X. refers to a panelist who left the panel after the third round.
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statements wasmodified in the iteration from the second to the
third round.
Statistical analysis
All ratings of panellists for each statement were analysed with
descriptive statistics measuring the mean score, the maximum
and minimum score, and the standard deviation.
A mean score of 4 was considered a good agreement be-
tween panellists and a score of 5 a complete agreement.
After the second round, the facilitator collected the ratings
from the panellists and calculated the score of agreement for
each statement. If the mean score was less than 4, the facilita-
tor asked the panellists to review the statement and reach a
higher level of agreement by changing the content and, when
necessary, the number of the statements.
To measure the internal consistency of the panellists ratings
for each cluster of statements, a quality analysis based on the
average inter-item correlation was performed with Cronbach's
alpha (Cα) correlation coefficient, using SPSS (SPSS, Chica-
go, IL, USA) [19, 20]. The Cα test provides a measure of the
internal consistency of a test or scale; it is expressed as a
number between 0 and 1. Internal consistency describes the
extent to which all the items in a test measure the same con-
cept. Cα was determined after each round.
The closer Cα coefficient is to 1.0, the greater the internal
consistency of the items in the scale. An alpha coefficient
(α)>0.9 was considered excellent, α>0.8 Good, α>0.7 Ac-
ceptable, α>0.6 Questionable, α>0.5 Poor, and α<0.5 Un-
acceptable. However, in the iterations a α of 0.8 was consid-
ered a reasonable goal for internal reliability.
Results
In the second round, the panel elaborated 94 statements. These
were reduced to 76 in the third round (Table 1). The overall
mean score of agreement of the experts was 4.72 (standard
deviation SD ±0.22) in the second round and improved to 4.84
(SD ±0.17) in the third round. From the second to the third
round, the panel reached complete consensus (rating 5), re-
spectively, in 12/93 (12 %) and 17/76 (22 %) statements.
Meanwhile, in the remaining statements, in both rounds, no
expert rated any individual statement less than 4, confirming,
despite the apparent heterogeneity of the sample, that there
was generally some agreement amongst them.
Full consensus was reached by the experts panel in 22 % of
the statements. In the remaining statements, full consensus
was not reached, but all the panellists achieved a Bgood^ level
of agreement.
The highest mean level of agreement (4.87±0.21) and
questionable internal consistency (Cα 0.67) was reached by
the WG1 (MR technique), with full consensus on the
statements about the use of MR coils, type of contrast agent,
and the specific MR sequences to be used in liver MR
examinations.
The highest number of statements (6/18; 33 %) having full
consensus were in the WG4, with a good mean level of agree-
ment (4.85±0.15) and questionable internal consistency (Cα
0.61). Such statements clearly addressed the proposed Bstate–
of-the-art^ MR protocol and the enhancement pattern ob-
served with liver-specific contrast agents of focal liver lesions
in cirrhotic patients.
Discussion
Along the entire consensus process, the experts completed
three rounds; the first round served to elaborate the basic
statements, whereas the second and third rounds contained
the core of the discussion and were necessary to reach the
maximum consensus, in order to create an optimized and ho-
mogeneous opinion for each statement. Finally, the overall
mean score of the panellists was 4.84 (SD ±0.17), which
should be considered an almost excellent result of agreement.
The Cronbach’s test used in the study had the value of an
additional measure of consistency of the consensus rounds;
the highest Cα were obtained in the Wg1 and WG4, but with
a questionable internal consistency (0.6<Cα <0.7). In the re-
maining WGs the Cα was below an acceptable level. These
results do not imply unreliability of the consensus; in fact,
from a practical point of view, such results are related to the
high number of panellists (n=18) that inevitably raised the
variability in the score of agreement. However, such hetero-
geneity of scores (all higher than 4) did not significantly im-
pact the mean level of agreement. Moreover, this reflects the
mediating role played by the two facilitators of the consensus
that allowed pushing the levels of agreement above the thresh-
old of 4.
All panellists exhibited a high level of agreement for the
MR technique with clear recommendations regarding the use
of MR coils, type of contrast agent, and the specific MR se-
quences to be used in liver MR examinations. These data
reflect a consolidated approach to liver MR examination with
no significant difference among panel members despite their
wide geographical spread. All panel members, belonging to
academic and non-academic centres, are regular speakers of
ESGAR meetings/workshops, a condition that may have fa-
cilitated the information sharing in this field of expertise and,
therefore, improved their level of agreement.
However, even if this condition may have facilitated the
agreement, the recruitment of experts and specialist belonging
to the same peer group does not necessarily compromise ex-
pertise. But it has to be taken into account that there is a risk of
mutual influencing of opinions and attitudes. A way to over-
come this bias would have been to include panel members
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with expertise in other specialized areas such as hepatology,
surgery, and methodology, and a representation from sister
medical societies.
As a basic rule of MR technique, all the panellists clearly
addressed that the workup of solid focal liver lesions should
include axial T2- and T1-weighted sequences, followed by
T1-weighted gradient dual echo images, DWI (using low
and high b-values) and dynamic contrast-enhanced T1-
weighted fat-saturated (see statement 10 in Table 1). Howev-
er, no full consensus was reached on statements 1 and 2 that
addressed similar results of MR imaging at 3 and 1.5 T. This
incomplete agreement can be explained by the discrepancies
of the comparative studies on the use of 1.5 vs. 3 T MRI
[21–24].
The remaining statements regarding MRI technique, even
with less than Bfull^ consensus, definitively addressed the
modalities of contrast medium administration (flow-rate of
1–2 mL/s followed by a 20-mL saline flush at 1–2 mL/s using
a bolus triggering technique ) and timing of T2-weighted and
DWI sequences (after the acquisition of the contrast-enhanced
late dynamic phase).
With regards to the recommendations on the use of the
gadobenate dimeglumine (Gd-BOPTA) and the gadoxetic ac-
id (Gd-EOB-DTPA) that are the currently available on the
market, the panel was aware there are no data indicating diag-
nostic superiority of one agent over the other. It must also be
noted that to our knowledge there are very few publications
comparing Gd-EOB-DTPA and Gd-BOPTA [25–27].
All panellists fully agreed that all non-blood pool gadolin-
ium chelate-based contrast agents are suitable for dynamic
liver MRI, but the use of liver-specific contrast agents is man-
datory to obtain the hepatobiliary phase in addition to the
dynamic phase (statements 4 and 5). Jeong et al emphasized
that the "hepatobiliary" phase is where uptake by the hepato-
cytes and excretion to the bile ductule have reached an optimal
level for diagnosis [28]. Kim et al demonstrated no statistically
significant difference in the signal intensity of liver parenchy-
ma in the arterial phase between gadobenate dimeglumine and
gadoxetic acid [28], and Filippone et al showed a statistically
significant higher signal intensity of gadoxetic acid-enhanced
MR in the hepatobiliary phase [29]. In a recent article, Ba-
Ssalamah et al stated that liver specific contrast agents provide
a multiparametric assessment of hepatobiliary diseases, since
they combine morphologic and functional information in the
same setting and, therefore, can play the role of imaging bio-
markers [30].
A mean good level of agreement was reached between the
panellists regarding the application of liver specific contrast
agents in benign hepatocellular liver lesions, and addressed
MRI as the preferred imaging modality for the characteriza-
tion of equivocal focal lesions detected by other imaging
modalities (statement 18). The added value of Gd-BOPTA
in the evaluation of solid hepatic lesions is supported by
literature evidence. Grazioli et al, through a quantitative anal-
ysis of signal intensity, lesion-to-liver contrast, and enhance-
ment ratio, demonstrated that Gadoxetic acid-enhanced MR
imaging facilitates the differential diagnosis of hepatocellular
adenoma (HCA) and focal nodular hyperplasia (FNH) [31].
The same author showed in a previous article that this was
possible with Gd-BOPTA [32]. Haimerl et al andMorana et al
showed that the hepatobiliary phase images obtained after Gd-
EOB-DTPA-enhanced dynamic MRI significantly improved
the index of diagnostic performance in the differentiation of
focal solid lesions [33, 34].
A mean good level of agreement was also reached between
the panellists on the cluster of statements about malignant
liver lesions in non-cirrhotic patients, where the use of
liver-specific contrast agents has been recommended to im-
prove the differential diagnosis between a solid benign hepa-
tocellular lesion and metastasis, and delineation of primary
liver tumors (including intrahepatic or mass-forming
cholangiocarcinoma). In a recent study comparing the diag-
nostic performance of MDCT and gadoxetic acid-enhanced
MRI at 3.0, Scharitzer et al found that MRI with the liver-
specific contrast agent had better performance in the assess-
ment of small colorectal liver metastases [35]. A similar study
comparing MDCT and MRI performed by Kim et al, showed
higher diagnostic accuracy for MRI in the detection of hepatic
metastases and for the differential diagnosis with hepatic
haemangiomas or cysts [36]. However, a hypointense pattern
in the hepatobiliary phase has been reported by Han et al [37]
as a potential pitfall of liver-specific contrast agents agents in
patients who received oxaliplatin as part of their chemothera-
py regimen. Specifically, in these patients, due to the sinusoi-
dal obstruction syndrome (focal hepatopathy), the morpholog-
ic pattern of the hypointensity at the hepatobiliary phase may
contribute to avoid this potential pitfall.
With regard to mass-forming cholangiocarcinoma, the pan-
el clearly stated that concerning the delayed phase enhance-
ment obtained with non-specific extracellular agents, Gd-
EOB provides a relative hypointenseMRI pattern of the lesion
both in the transitional and hepatobiliary phases that improves
tumour conspicuity [38]. The panel suggested also the use of
DWI and perfusions techniques, and recently, Park et al dem-
onstrated that the target appearance seen on the DWI was the
most reliable imaging feature for distinguishing small mass-
forming peripheral cholangiocarcinoma from small HCC [39].
The best agreement among the panellists was reached for
focal liver lesions in cirrhotic patients. The panel stated with
full agreement that a confident diagnosis of HCC by using a
complete dynamic study with pre-contrast and multiphase
sequences (statement 34), can be optimally reached with a late
hepatic arterial phase over early arterial phase (statement
35), and the hepatobiliary phase may be delayed depending
on a reduced liver function (statement 38) [40, 41]. Haimerl
et al demonstrated that regarding comparability with the
928 Eur Radiol (2016) 26:921–931
MELD (Model for End-Stage Liver Disease) score, decreased
Gd-EOB-DTPA accumulation in the hepatocytes during the
hepatobiliary phase, and T1 relaxometry correlated with re-
duced liver function [42]. Verloh et al also found that the
relative enhancement during hepatobiliary phase in GD-
EOB-DTPA MRI correlates with the MELD score [43].
Of note, the panellists addressed that the use of liver-
specific contrast agents has particular usefulness in improving
the detection of HCC. In fact, while statements 41, 42, and 43
clearly address the definition of wash-in and wash-out (higher
signal intensity than the surrounding parenchyma in arterial
phase, lower signal intensity in the portal phase after injection
of Gd-chelates), statement 48 addresses the importance of the
hepatobiliary phase to differentiate between HCC and arterial-
enhancing pseudolesion when using liver specific contrast
media.
Cereser et al have shown that the delayed phase is superior
to the portal venous phase for the wash-out detection in
hypervascular HCC with Gd-BOPTA MRI in the cirrhotic
liver. This is one of the limitations of Gd-EOB-DTPA, where
the hypointensity on the 3–5 min delayed phase, also called
the transitional phase, is less effective in detecting washout as
it blends into the liver specific phase. Accordingly, often
wash-out cannot be assessed with Gd-EOB-DTPA [44].
In a study performed by Bartolozzi et al the hyperintensity
on the arterial phase and hypointensity on the transitional
phase were highly predictive for HCC, but a further element
of HCC diagnosis was the hypointensity on hepatobiliary
phase, evident in 39 out of 40 the HCC detected in the study
cohort with a 100 % positive predictive value in suggesting
nodular premalignancy/malignancy [45]. Yu et al supported
the same statement, and has since demonstrated that even the
detection of small HCC nodule (<1 cm) in a standard multi-
phasic study can be improved by the addition of the
hypointensity pattern on the hepatobiliary phase [46]. Granito
et al found that hypointensity during the MR hepatobiliary
phase was observed in all HCC nodules of the study and
concluded that gadoxetic acid MRI may enhance the sensitiv-
ity of the non-invasive diagnosis of small hepatocellular car-
cinoma nodules in cirrhotic patients under surveillance [47].
In summary, the panel suggests that in cirrhotic patients, the
hepatic arterial phase and portal venous phase might not be
sufficient to establish a confident diagnosis of HCC and
should be integrated by the hepatobiliary phase.
No statement reached full agreement for diffuse and vas-
cular liver diseases, and it was acknowledged that a correct
estimate of the degree of steatosis and iron overload needs
multiparametric MRI, even if the administration of contrast
agents may alter the quantification of fat and iron liver con-
tent. Even with the support of the few literature studies avail-
able, the use of liver-specific contrast agents was specifically
indicated to evaluate multiacinar regenerative nodules in pa-
tients with vascular disorders (statement 59) in the study of the
sinusoidal obstruction syndrome (statement 60) and in the
detection of vascular and biliary complications after transplan-
tation (statement 63). In a study by Katajiama et al, the hepatic
congestion and oedema occurring in Budd-Chiari syndrome
were seen as slightly hypointense areas on Gd-EOB-DTPA-
enhanced hepatobiliary-phase images, and such a pattern im-
proved the diagnosis of sinusoidal obstruction syndrome with
respect to Gd-DTPA enhancement [48]. In a recent study, Shin
et al confirmed that Gd-EOB provides a peculiar reticular
hypointensity pattern on hepatobiliary phase images and that
is highly specific for the diagnosis of sinusoidal obstruction
syndrome in patients with treated colorectal hepatic metasta-
ses [49].
The final cluster of statements indicates that the evaluation
of the biliary tract should be an integrant part of the liver study,
and MRCP should be performed on pre-contrast series with
heavily 2D and/or 3D T2-weighted sequences. It should be
taken into account that in the absence of liver function
impairment/biliary obstruction, contrast-enhanced MR chol-
angiography (MRC) can be optimally obtained with Gd-
EOB-DTPA at 20 min after injection (statements 66 and 68).
Hepatic excretion of liver-specific contrast agents results in
enhancement of biliary structures, and it is likely to have a
great impact on better visualization of biliary system. On the
basis of these characteristics, it may potentially increase reli-
ability of the MR examination or decrease the occurrence of a
non-diagnostic or equivocal interpretation [50]. This emerging
diagnostic tool, especially when using Gd-EOB-DTPA, is par-
ticularly helpful for delineating the anatomy of the biliary tract
and detecting post-operative complications such as anasto-
motic and non-anastomotic strictures and biliary leaks. In ad-
dition, it can provide functional information that is extremely
promising in the grading of biliary obstruction. Recently,
Boraschi et al in review papers showed the usefulness of
Gd-EOB in the evaluation of biliary-enteric anastomoses
and in the assessment of biliary complications after orthotopic
liver transplantation [51, 52]. The drawbacks of contrast-
enhanced MRC include its high cost (it is also a time-
consuming technique) and limitations in depicting the biliary
system in patients with hepatobiliary dysfunction.
Conclusion
The panel of the ESGAR working group covered most impor-
tant aspects of liver MRI methodology combined with the
clinical use of liver-specific contrast agents, and reached a
good level of agreement on most statements. As a result of
the consensus process, the working group provided updated
recommendations on the best use of MRI in the study of liver
diseases.
Such recommendations should be helpful for both the ra-
diologist who is startingMR imaging of the liver and for those
Eur Radiol (2016) 26:921–931 929
who have already applied the technique, but whose practice
may need updating in the light of more recent developments.
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